intrexon

We are a community of scientists and creative innovators working to build a safer, healthier planet, and a more promising future. (NASDAQ: $XON)

[intrexon @Intrexon]

#Precigen completes series of transactions to solidify healthcare focus. Name changes to @Precigen from @Intrexon and ticker symbol to @Nasdaq: $PGEN #Maryland #biopharma #GeneTherapy #CellTherapy #Immunotherapy https://t.co/gXPkOdZ3aj

[intrexon @Intrexon]

Triple-Gene to highlight its investigational #genetherapy in Phase 1 for treatment of #heartfailure at #BiotechShowcase TODAY January 15th at 11:30am PT in Franciscan B at the Hilton San Francisco Union Square $XON #Precigen #cardiovasculardisease #JPMHC20 #JPM2020 #JPMorgan2020

[intrexon @Intrexon]

At #JPMHC20? Listen to Dr. Helen Sabzevari, President & CEO of @Precigen, at 5pm PT in California West present on #Precigen progress and 2020 look ahead OR watch live webcast here: https://t.co/IgWo7QQDK4 $XON #JPM2020 #JPMorgan2020 #GeneTherapy #CellTherapy #Immunotherapy

[Precigen @Precigen]

Join Dr. Helen Sabzevari, President and CEO of Precigen, at #JPM20 for her presentation on Precigen’s progress and a 2020 look ahead. #GeneTherapy #CellTherapy #Immunotherapy #Biotech #Maryland $XON https://t.co/5JXIfmAlYk

[intrexon @Intrexon]

Triple-Gene to highlight advantages of its multigenic approach for treatment of #heartfailure at #BiotechShowcase on January 15th, 2020 at 11:30AM PT at the Hilton San Francisco Union Square. Read more here: https://t.co/Q3nPFzlqaT #cardiovasculardisease #genetherapy $XON

[Washington Business Journal @WBJonline]

Just four days after Germantown's Intrexon Corp. made public plans to rebrand as Precigen, its subsidiary by the same name has secured a coveted regulatory designation for its blood cancer treatment. https://t.co/T91UgjgIMe

[Precigen @Precigen]

#Precigen receives first regulatory designation for PRGN-3006 UltraCAR-T #OrphanDrugDesignation #immunotherapy #biotech https://t.co/IZTsW7u3B9

[intrexon @Intrexon]

$XON To Achieve $175M Cash Goal, Appoints Helen Sabzevari, PhD, As New President And CEO And Will Change Name To @Precigen To Reflect Healthcare Focus. Read more here: https://t.co/58t48P9Ygo #immunotherapy #genetherapy #Maryland #biotech

[Precigen @Precigen]

#Precigen’s Tim Chan to present preclinical data from PRGN-3006 UltraCAR-T at #ASH2019 in Orlando, FL #CellTherapy #AML #MDS #BloodCancer #Immunotherapy https://t.co/1OoyjQ573m

[Precigen @Precigen]

Dr. Helen Sabzevari, President of #Precigen, will speak at the upcoming World Vaccine & Immunotherapy Congress in San Francisco. Join us! https://t.co/0mun7TIEIu #immunotherapy #UltraCAR-T #oncology #CellTherapy #MarylandInnovates $XON

[Precigen ActoBio @ActobioT]

Great news from our partners at #Oragenics! Enrollment is now complete for their phase 2 clinical trial of AG013 for #oralmucositis. AG013 is an ActoBio Therapeutics Inc. candidate created on our #ActoBiotics® platform and licensed to Oragenics. More: https://t.co/rrnQzmKruO

[intrexon @Intrexon]

$XON subsidiary Triple-Gene presented preliminary phase 1 trial data of investigational multigenic therapeutic candidate INXN 4001 for treatment of #heartfailure at
#AHA19. Discover more: https://t.co/NFuBG2vqtL and https://t.co/Jn2eLrxr1k #cardiovasculardisease #genetherapy

[intrexon @Intrexon]

Discover more about Triple-Gene’s approach to address #heartfailure: @physicianswkly highlights “The Heart of the Matter: Leveraging Advances in Cardiac Biology to Innovate Gene-Based Therapies for Heart Failure” https://t.co/yBNqbsKxcB $XON #cardiovasculardisease #genetherapy

[intrexon @Intrexon]

Intrexon Reports Third Quarter Financial Results: https://t.co/F79e85Sqjh. @Precigen to host conference call today at 11am ET to provide Precigen business and pipeline updates. Register for call here: https://t.co/kEgTeTfVLK $XON #immunotherapy #genetherapy #celltherapy

[intrexon @Intrexon]

Intrexon subsidiary Triple-Gene announces completion of dosing in Phase 1 trial of INXN-4001, first multigenic investigational #genetherapy candidate for treatment of #heartfailure. Learn more here: https://t.co/E16G1kuvXV $XON #cardiovasculardisease

[intrexon @Intrexon]

$XON to Announce Third Quarter Financial Results on Nov 12th. @Precigen to host conference call that day at 11am ET to provide Precigen business and pipeline updates. To learn more and register, click here: https://t.co/1Zyb0c4gnk #immunotherapy #genetherapy #celltherapy

[intrexon @Intrexon]

At #BIOInvestorForum? Don’t miss #ActoBio Therapeutics™ CEO Pieter Rottiers presenting an overview of the innovative ActoBiotics® platform today Wednesday October 23 @ 9:15 AM PT. Read more: https://t.co/gduXqQFb5n or follow us on LinkedIn or Twitter @ActobioT #bif19 #biotech

[intrexon @Intrexon]

At #SynBioBeta? Don't miss #ActoBio Therapeutics™ CEO Pieter Rottiers' presentation at 4PM today about the innovative ActoBiotics® platform. More: https://t.co/hTdXyaguGj or follow on Twitter @ActobioT or LinkedIn. #actobiotics #healthcare #biotech

[intrexon @Intrexon]

David Witte formerly of @IHSMarkit to lead MBP Titan LLC, standalone subsidiary company of Intrexon comprising Intrexon’s #Methane #Bioconversion Platform. Discover more: https://t.co/OddmaxFVID. $XON #energy #bioengineering #betterDNA

[Precigen ActoBio @ActobioT]

If you're attending #SynBioBeta2019 don't miss #ActoBio Therapeutics™ CEO Pieter Rottiers' overview of the innovative #ActoBiotics® platform and its applications on October 1. Read more: https://t.co/rrnQzmsQ6e, follow us on Linkedin or Twitter @ActobioT #biotech #immunology